3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
33
Breast Neoplasms
27
Carcinoma, Non-Small-Cell Lung
22
Triple Negative Breast Neoplasms
19
Ovarian Neoplasms
18
Lung Neoplasms
18
Fallopian Tube Neoplasms
17
Neoplasm Metastasis
15
Squamous Cell Carcinoma of Head and Neck
12
Endometrial Neoplasms
10
Neoplasms
9
Oropharyngeal Neoplasms
6
Mouth Neoplasms
6
Esophageal Neoplasms
6
Cholangiocarcinoma
6
Melanoma
5
Colorectal Neoplasms
5
Carcinoma
5
Adenocarcinoma Of Esophagus
5
Stomach Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Carcinoma, Transitional Cell
4
Anatomic Stage I Breast Cancer AJCC v8
4
Pancreatic Adenocarcinoma
3
Inflammatory Breast Neoplasms
3
Head and Neck Neoplasms
3
Gallbladder Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Squamous Cell
3
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Taxes
×
1 year
×
Clear all
NCT07049055
2026-02-27
Carolyn-USA
Engeneic Pty Limited
Phase 1/2
Recruiting
144 enrolled